Found this very bullish post on another board. This is from the Konlin Letter:
"EFSF is a pioneering company with stunning breakthrough
technology on the verge of explosive revenue growth. EFSF is
dedicated to improving health conditions around the world through
its proprietary innovative technologies with products entering multibillion
dollar markets. EFSF believes it has formulated the “Total
Solution” to the potential Avian Influenza (Bird Flu) pandemic.
Its Knock-Out Technologies, Ltd. subsidiary has developed a revolutionary,
environmentally safe sporocidal product formulated entirely
of food-grade components that eradicates the most lethal of all
biological weapons, Anthrax, and a germicidal product Citroxin (EPA
REG#82723-1) that kills six major bacteria: E-coli, Listeria, Pseudomonas,
Salmonella, Staphylococcus, Streptococcus, and is 100% effective at
wiping out Black Mold (stachybotrys chartarum), which is overrunning
hurricane-ravaged areas in the Gulf Coast. Most important, it could
become the anti-viral prophylaxis (applying the remedy before the
cure), the total solution of choice for the deadly Bird Flu.
EFSF’s MedElite, Inc. subsidiary distributes clinically proven
products to physicians who then prescribe them to their patients. It
is the exclusive worldwide and U.S. distributor of the Talsyn™-Ci/bid
Scar Cream that has been clinically proven to facilitate and improve
the appearance, redness, and strength of scars. It is one of the most
efficacious scar creams on the market today, entering a $4 bil. market.
The potential is huge. EFSF is also a distributor for Cinnergen™, a nonprescription
liquid whole food nutritional supplement that promotes
healthy glucose metabolism and Trimmendous™, a weight loss
formula focusing on the body’s 24-hr. metabolic processes.
Health professionals have been aware of the adverse health effects
of exposure to mold for decades. Studies indicate that 50% of all homes
contain certain molds and the dramatic increase in asthma over the
past 20-yrs. can be attributed to mold exposure. Toxic mold can form
on most building surfaces and products (dry wall, insulation, ceiling
tiles, carpet, etc.) if it remains wet for 24-48 hours. Citroxin Cleaner can
significantly reduce costs of the rapidly growing new sector of the
environmental remediation industry—toxic mold.
EFSF continues its massive Direct Response Marketing Campaign
via radio and TV for its Cinnergen™ Diabetes product (a $132 bil.
market). Diabetes is becoming one of the fastest growing chronic
health problems in America’s aging population. Cinnergen™ encapsulates
a proven effective naturally occurring compound found in
cinnamon that can supplement subscription diabetes medications
(Type 1 diabetic patients) and help decrease medication needs in Type
2 diabetic and borderline patients. Sales have exceeded expectations
with their marques of companies including, General Nutrition Centers
(GNC-over 5,000 related locations worldwide), The Vitamin Shoppe
(over 260 retail locations in the U.S.), Kinray, Inc., the largest privately
held distributor of pharmaceutical, generic and health and beauty care
products in the world (sales in excess of $3.5 annually), The F. Dohmen
Co., a wholesale distributor serving the pharmacy industry for over 140
years and Smith Drug Co. (division of J.M Smith Corp., 6th largest
privately held company) serving over 1,000 pharmacies in the midsoutheast
U.S.
In less than a year of a major restructuring, EFSF has generated
sales for the 1st 9 mos. FY’06 of $116,008, with a loss per share of (.04).
EFSF anticipates to be profitable for Q1’06 on an operational basis
with sales exceeding all of FY’05. The company has virtually no debt
and of the 128,674,000 shares outstanding, approx. 60% are held
by insiders. The stock, testing support since Sept. '05, successfully
achieved higher lows. It is on the verge of completing a short-term
double bottom for the launching of its next up-leg. The huge short
position is the fuel to drive it to our 1st target of 2.00, but it must first
close above .8750.
This ground floor opportunity with explosive
growth potential has already established positive fundamentals, and
has more products in the pipeline (some already generating revenue)
that could see sales growth of $8 mil. in the next 10 mos., especially as
it enters into a multi-million-dollar worldwide direct marketing
campaign to sell its anti-acne product with a high-profile celebrity
spokesperson. Worldwide appeal for the product could easily approach
$200mil.as the leading competitor’s sales exceeded $300 mil. last year.
EFSF has entered the biotech arena with its revolutionary Lyme’s
Disease product; human clinical trials are currently underway with
EFSF’s safe, natural, ingestible product that is believed to offer a
positive treatment for chronic Lyme’s Disease. In ’03, the National
Center of Infectious Diseases estimated annual cost for treatment of
disease at $60 mil. a year in the U.S. EFSF is also on the verge of entering
the $33 bil. domestic market of obesity to sell Trimmendous™, an
all-natural (effedrine-free) weight loss formula that has unique
selling and performance benefits that could readily capture significant
market share. Our original target has been $4-$6, but with products
coming on line better than anticipated with positive lab results, along
with EFSF’s total solution to the Bird Flu, and with live testing about
to begin, the stock could soar.
Yes, I own the stock and believe in both
the company and its management"
News 
Market Data 
Discover 
